A Phase 1, Randomized, Participant- and Investigator-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3541860 in Healthy Japanese and Non-Japanese Participants
Latest Information Update: 09 Dec 2024
At a glance
- Drugs LY 3541860 (Primary) ; LY 3541860 (Primary)
- Indications Autoimmune disorders; Multiple sclerosis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 04 Apr 2024 Status changed from active, no longer recruiting to completed.
- 08 May 2023 Planned End Date changed from 3 Jul 2023 to 26 Jun 2024.
- 08 May 2023 Planned primary completion date changed from 3 Jul 2023 to 26 Jun 2024.